In vivo absorbable photocurable composition, in vivo absorbable tissue regeneration inducing material comprising same, and transplantation method using same

By applying a composition of photosensitive agent and collagen on the transplanted material and using visible light to activate it, the problem of insufficient adhesion of traditional transplanted materials is solved, and stable fixation and tissue regeneration of the transplanted material is achieved, combining antibacterial or anti-inflammatory functions.

CN119031944APending Publication Date: 2024-11-26NIBEC +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202380021931.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-15
Filing Date
2023-02-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Traditional transplant materials are difficult to maintain adhesion in the body, resulting in a reduced transplant success rate.

Method used

Using an in vivo absorbable photocurable composition containing photosensitive agent and collagen, the photosensitive agent is activated by irradiation of visible light, collagen is cross-linked and filled with fine voids in the transplant site, and the transplant material is fixed to ensure that it fits with the transplant material.

Benefits of technology

Effectively prevent the loss of transplanted materials, maintain adhesion, promote tissue regeneration, and can combine anti-inflammatory or antimicrobial peptides to enhance the function of transplanted materials.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119031944A_ABST
    Figure CN119031944A_ABST
Patent Text Reader

Abstract

Provided are an in vivo absorbable photocurable composition, an in vivo absorbable tissue regeneration inducing material comprising the same, and a transplantation method using the same. The in-vivo absorbable photocurable composition contains a photosensitizer and collagen, is applied to the top of an in-vivo transplantation site filled with a transplantation material, fills voids in the transplantation site, and covers the transplantation material, and when irradiated with visible light, the photosensitizer is activated, the collagen is crosslinked, and the in-vivo absorbable photocurable composition is obtained. The visible light cross-linked collagen fills the fine voids of the transplantation site, and adheres to the transplantation material to fix the transplantation material.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an in vivo absorbable photocurable composition, an in vivo absorbable tissue regeneration inducing material containing the composition, and a transplantation method using the same. Background Art

[0002] In order to treat various bone loss or defects (hereinafter referred to as damage) caused by inflammation, tumors, trauma, bone diseases, etc., it is necessary to fill the loss or defect site with a transplant material. However, if only the damaged site is filled with a transplant material, there is a disadvantage that the transplant material is difficult to maintain at the transplant site.

[0003] Therefore, traditionally, Figure 1 As shown in , tissue regeneration is induced by filling the damaged area with a graft material, covering it with a barrier membrane, suturing the barrier membrane once, and then covering the skin with a second suturing. Figure 1 As shown, when the transplant material and the barrier membrane are used at the same time, regeneration can only be successfully achieved if the transplant material implanted at the bottom and the barrier membrane at the top adhere to each other. However, it is difficult to obtain perfect adhesion between the transplant material and the barrier membrane, so a gap will appear between the transplant material and the barrier membrane, resulting in a reduced transplant success rate.

[0004] Therefore, a new material and transplantation method are needed that can prevent the loss of transplanted material while maintaining adhesion. Summary of the invention

[0005] Technical issues

[0006] The present disclosure aims to provide an in vivo absorbable photocurable composition that can prevent the loss of transplant materials while maintaining adhesion.

[0007] The present disclosure aims to provide an in vivo absorbable tissue regeneration inducing material, which comprises an in vivo absorbable photocurable composition.

[0008] The present disclosure aims to provide a transplantation method.

[0009] Technical Solution

[0010] According to the embodiment, the in vivo absorbable photocurable composition comprises a photosensitizer and collagen, which is coated on the top of the in vivo transplantation site filled with the transplantation material to fill the gaps in the transplantation site and cover the transplantation material. The photosensitizer is activated by irradiation with visible light, and the collagen is cross-linked, so that the collagen fills the fine gaps in the transplantation site and adheres to the transplantation material to fix the transplantation material.

[0011] According to the embodiment, the in vivo absorbable tissue regeneration inducing material comprises a transplant material and an in vivo absorbable photocurable composition, wherein the transplant material comprises a first agent and a second agent, wherein the first agent comprises collagen as a main component, and the second agent comprises a peptide formulated to be able to impregnate the first agent, and the in vivo absorbable photocurable composition comprises a photosensitizer and collagen, which is applied to the transplant site filled with the transplant material to fill the gaps in the transplant site and cover the transplant material, and the photosensitizer is activated by irradiation with visible light, and the collagen is cross-linked, so that the collagen fills the fine gaps in the transplant site and adheres to the transplant material to fix the transplant material.

[0012] According to the transplantation method of the embodiment, it includes: the step of filling the transplantation material into the transplantation site in the body; the step of applying an in vivo absorbable photocurable composition containing a photosensitizer and collagen on the top of the transplantation site filled with the transplantation material to fill the gaps in the transplantation site and cover the transplantation material; and the step of irradiating visible light to the in vivo absorbable photocurable composition, the photosensitizer is activated, so that the collagen is cross-linked, the collagen cross-linked by the visible light fills the fine gaps in the transplantation site, and adheres to the transplantation material to fix the transplantation material.

[0013] Details of other aspects of the invention are included in the detailed description which follows.

[0014] Effects of the Invention

[0015] According to the in vivo absorbable photocurable composition and the transplantation method using the same, after the in vivo absorbable photocurable composition covers the top surface of the transplant material and fills the remaining gaps in the transplant site filled with the transplant material, the micro gaps in the transplant site can be filled and adhered to the transplant material. Therefore, the loss of the transplant material can be prevented, and the adhesion with the transplant material can be maintained, so that tissue regeneration can occur effectively.

[0016] According to the tissue regeneration inducing material of the embodiment and the tissue regeneration inducing method using the same, a transplant material with anti-inflammatory or antibacterial ability is used together with an in vivo absorbable photocurable composition to exert anti-inflammatory or antibacterial functions, which can effectively form the microenvironment factors required for tissue regeneration, while preventing the loss of the transplant material and maintaining the adhesion with the transplant material, so that tissue regeneration can occur effectively. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a schematic diagram showing the conventional general bone transplantation surgery process.

[0018] Figure 2 is a flow chart illustrating a migration method according to one embodiment.

[0019] Figure 3 This is a schematic diagram of the process of photocuring in a photocurable composition.

[0020] Figure 4 This is the result of analyzing the purity of the peptide using liquid chromatography after synthesis. The peptide has the amino acid sequence of SEQ ID NO: 1.

[0021] Figure 5 This is the result of analyzing the molecular weight of a peptide synthesized by mass spectrometry. The peptide has the amino acid sequence of SEQ ID NO: 1.

[0022] Figure 6 The results of enzyme immunoassay (ELISA) for IL-6 and TNF-α are shown.

[0023] Figure 7 The results of Western blot analysis of pNFkB and plkBa are shown.

[0024] Figure 8 The results of measuring the antibacterial ability of a peptide having the amino acid sequence of SEQ ID NO: 1 are shown.

[0025] Fig. 9 The results of treating biofilms with a peptide having the amino acid sequence of SEQ ID NO: 1 are shown.

[0026] Fig.10 The graph shows the results of analyzing the intracellular penetration of a peptide having the amino acid sequence of SEQ ID NO: 1 using a confocal microscope.

[0027] Fig.11 The degree of intracellular penetration of a peptide having the amino acid sequence of SEQ ID NO: 1 into rabbit gingival tissue is shown.

[0028] Fig.12 The extent of intracellular penetration of a peptide having the amino acid sequence of SEQ ID NO: 1 into adult canine gingival tissue is shown.

[0029] Fig.13 The results of measuring the antibacterial ability of a collagen sponge containing a peptide having the amino acid sequence of SEQ ID NO: 1 are shown.

[0030] Fig.14 and Fig.15 Numerical values ​​indicate the results of periodontal tissue regeneration and the degree of alveolar bone regeneration confirmed by radiography in an adult canine periodontitis model treated with a collagen gel containing a peptide having the amino acid sequence of SEQ ID NO: 1. The squares indicate the alveolar bone regenerated by the transplant material.

[0031] Fig.16These are photographs showing the state of gel formation according to changes in the collagen content in the photocurable composition.

[0032] Fig.17 These are photographs showing the state of gel formation according to changes in the riboflavin content in the photocurable composition.

[0033] Fig.18 These are photographs showing the state of gel formation according to changes in the NaOH content in the photocurable composition.

[0034] Fig.19 These are photographs showing changes in properties of riboflavin-containing collagen gels upon light irradiation.

[0035] Fig. 20 It is a bar graph showing the results of measuring the viscosity of the riboflavin-containing collagen gel before and after solidification.

[0036] Fig.21 These are photographs showing the stability of collagen gel containing riboflavin.

[0037] Fig. 22 The photographs show the implantation procedure of an adult dog suffering from peri-implantitis using a light-curable composition (collagen gel containing riboflavin). DETAILED DESCRIPTION

[0038] Hereinafter, the embodiments will be described in detail so that those skilled in the art can easily implement the present invention. The embodiments can be implemented in various ways and are not limited to the specific embodiments described herein.

[0039] Unless some terms used in the present disclosure are defined differently below, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0040] The techniques and processes described in the present disclosure are generally performed according to conventional methods, which are presented throughout the text. In general, the nomenclature used in the present disclosure and the laboratory procedures in molecular biology, biochemistry, analytical chemistry, and cell culture are well known in the art and are the same as commonly used.

[0041] The present invention relates to an in vivo absorbable photocurable composition and a transplantation method using the same. The in vivo transplantation site refers to a site including various bone loss or defects (hereinafter referred to as bone damage) caused by inflammation, tumor, trauma, bone disease, etc.

[0042] Bone injury sites may include dental injury sites and non-dental injury sites. For dental injury sites, the most representative ones are those caused by periodontal disease. Periodontal disease includes gingivitis limited to the gums, periodontitis in which the inflammation also spreads to the alveolar bone around the tooth root, and peri-implantitis, which is a complication caused by surgical implantation of artificial materials in the jawbone and affects the tissue around the implant, resulting in loss of supporting bone. In addition, dental injury sites may include dislocated traumatic tooth sites or extraction socket sites.

[0043] Non-dental injury sites can include a variety of injury sites, such as congenital injuries, injuries caused by cancer resection, acquired injuries caused by aging, bone degeneration and osteoporosis, and trauma-related injuries such as fractures.

[0044] like Figure 2 As shown, before the transplant site is filled with the transplant material, a pretreatment process (S1) may be performed.

[0045] For example, when treating periodontal disease typical of dental lesions, a regeneration process of periodontal tissue may be performed after scaling (scaling) and / or root planing treatments for removing plaque and tartar that cause periodontal disease.

[0046] Next, the transplant material is filled into the transplant site (S2).

[0047] The transplant materials may include transplant materials in various fields such as skin transplant materials, bone transplant materials, muscle bone regeneration materials, nerve regeneration materials, vascular regeneration materials, etc. For the transplant materials, basically, various transplant material matrices such as extracellular matrix proteins, bone minerals, chitosan, biodegradable polymers, etc. may be included.

[0048] The extracellular matrix protein may be any one or more selected from the group consisting of collagen, hyaluronic acid, elastin, chondroitin sulfate and fibroin. As these extracellular matrix proteins, those derived from humans and animals and recombinant proteins produced by microorganisms can be used.

[0049] Among the extracellular matrix proteins, collagen may be the most suitable. Collagen is formed by fibroblasts in the human body and is the main component of the most common connective tissue in the body. It is a fibrous protein distributed throughout the body such as bones, skin, joints, membranes of various organs and hair, etc. At the same time, a large amount of collagen is also present around the axons of the central and peripheral nerves. Since the collagen hydrogel present in the body has slightly different functions and effects according to the tissue position, the collagen concentration and orientation degree of the collagen hydrogel at each position are different. For example, the feature of bones is that there is a structure in which micron / nanocrystalline minerals are located between oriented collagen fibers. Collagen is an absorbent substance in the body. Due to easy decomposition, when implanted in the body, it can be gradually decomposed so that it is replaced by regenerated bone, so it is suitable as a transplant material matrix. For collagen, it is preferred to use type 1 or type 3 collagen separated from pig skin.

[0050] The bone mineral component may be one or more selected from the group consisting of biogenic bone mineral powder from allogeneic bone or xenogeneic bone, synthetic hydroxyapatite, and calcium phosphate cement (CPC) powder containing tetracalcium phosphate (TTCP), dicalcium phosphate anhydrous (DCPA), and monocalcium phosphate monohydrate (MCPM).

[0051] The biodegradable polymer may be any one or more selected from the group consisting of polyglycolide, polylactide, polyglycolide-lactide and polycaprolactone.

[0052] The graft material matrix can be in the form of a formulation consisting of a batter, powder, putty, gel, hydrogel, matrix, granules, particles, freeze-dried powder, freeze-dried bone, demineralized freeze-dried bone, fresh or fresh frozen bone, a mixture of cortical and cancellous bones, a pellet, a strip, a plug, a membrane, a freeze-dried powder returned to water to form a wet cake, a sphere, a sponge, a block, a morsel, a stick, a wedge, cement, or amorphous particles.

[0053] As required, the transplant material matrix may also contain therapeutic agents with anti-inflammatory, antibacterial or cell-permeable capabilities, etc. The therapeutic agent may be a peptide with anti-inflammatory, antibacterial or cell-permeable capabilities.

[0054] In one embodiment for treating dental injuries, the transplant material can be present as a combination of a first agent and a second agent, wherein the first agent has collagen as a main component, and the second agent contains a peptide and is formulated to be able to impregnate the first agent, and the first agent and the second agent can be mixed before transplantation and used.

[0055] The first dose with collagen as main component can comprise collagen sponge or collagen sponge and bone mineral complex of different sizes.If collagen powder is used, three-dimensional structure can not be formed, and then the environment that new tissue is easily regenerated can not be provided, so collagen sponge is preferably used.When being used for the treatment of dental injury, according to tooth sizes such as premolar, molar, collagen sponge of 6X5X7mm or 8X7X9mm, collagen sponge and bone mineral complex of 6X6X3mm, 6X6X6mm, 7X8X9mm or 9X10X11mm can be comprised.

[0056] The first dose and the second dose can be mixed before transplantation and used. When used after mixing before transplantation, it has the advantages of keeping collagen and peptides in a sterile state and maintaining a high peptide activity. This is because, in general, compared with storage in a solution state, storing proteins or peptides in a lyophilized state can be stored for a long time without reducing activity (activity), so if the peptide is stored in a lyophilized state and mixed into the collagen sponge before transplantation, it is possible to maintain a high peptide activity (anti-inflammatory ability, antibacterial ability, etc.) after transplantation.

[0057] In one aspect, the peptide formulated to be capable of impregnating the first agent constituting the implant material is a peptide having the amino acid sequence of Sequence 1 below.

[0058] Sequence 1: GKCSTRGRKSSRRKK

[0059] In one embodiment, after treatment with a peptide having the amino acid sequence of sequence 1, the intracellular release of inflammatory markers IL-6 and TNF-α was measured by enzyme immunoassay (ELISA), and it was confirmed that the peptide having the amino acid sequence of sequence 1 exhibited an anti-inflammatory ability that was almost similar to that of the cytokine IL-4 having an anti-inflammatory effect. In addition, the inhibitory effect of the peptide having the amino acid sequence of sequence 1 on the expression of the inflammation-related enzyme pNF-κB was confirmed by Western blotting, and the results confirmed that the peptide having the amino acid sequence of sequence 1 inhibited the expression of pNF-κB induced by LPS.

[0060] In another embodiment, it has been confirmed that the peptide having the amino acid sequence of SEQ ID NO. 1 has excellent antibacterial activity against periodontitis-causing bacteria such as Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis, and has been confirmed to exhibit the same or similar antibacterial activity as minocycline, which is commonly used in the treatment of periodontitis. In addition, the result of treating an artificial biofilm made with periodontitis-causing bacteria with the peptide having the amino acid sequence of SEQ ID NO. 1 confirmed that it has antibacterial activity and further has cell penetration ability.

[0061] In another aspect, the present disclosure relates to a peptide having cell-penetrating ability.

[0062] In one embodiment, it is confirmed by in vitro and in vivo experiments that a peptide having an amino acid sequence of sequence 1 penetrates into cells. Specifically, mouse macrophages (RAW264.7) were treated with a peptide having an amino acid sequence of sequence 1 to confirm whether they penetrate into the cells, and the result confirmed that the peptide having an amino acid sequence of sequence 1 penetrated into the cells. In addition, it has been confirmed that the peptide having an amino acid sequence of sequence 1 penetrates not only at the cellular level but also at the tissue level. When the gingival tissue of living rabbits and the gingival tissue of adult dogs were treated with a peptide having an amino acid sequence of sequence 1, it was confirmed that the peptide penetrated into the gingival tissue of rabbits and the gingival tissue of adult dogs.

[0063] In periodontitis or peri-implantitis, various periodontitis-inducing bacteria gather into communities to form thick biofilms. For this biofilm, it is difficult to remove it by only applying antibiotics because of the increased resistance to antibiotics. Therefore, it is necessary to penetrate this biofilm and at the same time have antibacterial ability to the periodontitis-inducing bacteria that constitute the biofilm. For the peptide with the amino acid sequence of sequence 1, it can penetrate into the cell itself, so there is no need to use an additional carrier. Therefore, it can penetrate the biofilm formed on the teeth and show antibacterial ability or easily penetrate into the gingival tissue. Further, by utilizing such cell / tissue penetration ability, the cell penetration ability is given by chemical conjugation with a peptide that has no cell penetration ability but has anti-inflammatory function, so that the desired anti-inflammatory effect can be increased.

[0064] In addition to the peptide having the amino acid sequence of sequence 1, as a peptide that can be mixed with collagen, the peptides of sequence numbers 2 to 5 disclosed in KR1249702, KR1320472, KR1329774, and KR1257228 applied for and registered by the present applicant can also be used, and these specifications are incorporated herein by reference.

[0065] Serial number 2: CPRRYKQIGTCGLPGTKCCKKP

[0066] Serial number 3: GKCSTRGRKCCRRKK

[0067] Serial number 4: RKIEIVRKKPIFKKATVT

[0068] Serial number 5: CKRKKKGKGLGKKRDPCLRKYK

[0069] The peptide as the second dose is dissolved in physiological saline, and the peptide solution is then placed in a tube for transplantation site injection, into which the first dose containing collagen as a main component is impregnated and then filled into the transplantation site.

[0070] The peptide may contain 10 -4 ~0.5 parts by weight, more preferably 10 -3 ~10 -1 This is because if the peptide content is less than 10 -3 If the peptide content is less than 0.5 parts by weight, the regeneration effect is not significant, and if the peptide content is greater than 0.5 parts by weight, it is difficult to include it in the transplant material.

[0071] Next, the in vivo absorbable photocurable composition is applied to the top of the in vivo implantation site filled with the implant material (S3).

[0072] The in vivo absorbable photocurable composition comprises collagen, a photosensitizer, a pH regulator and an isotonic agent. For the in vivo absorbable photocurable composition, when applied on the top of the transplantation site, it is applied in a gel state. Therefore, the viscosity of the in vivo absorbable photocurable composition has a viscosity that is easy to apply to the transplantation site, and can have a viscosity that does not drip. The viscosity of the in vivo absorbable photocurable composition can be in the range of 25 to 270 cP. Therefore, the in vivo absorbable photocurable composition can effectively fill the gap of the transplantation site filled with the transplantation material and cover the transplantation material.

[0073] Collagen can use type 1, type 2, type 3 or type 4 collagen solution, among which type 1 collagen can be effectively applied. This is because type 1 collagen is collagen derived from most connective tissues and is less likely to have a negative immune reaction with the tissue at the transplant site. The content of collagen can be in the range of 0.75-3w / v%. If the content is less than 0.75w / v% or greater than 3w / v%, it may not be sufficient to form a gel.

[0074] The photosensitizer may use a substance that can induce gelation of collagen by light irradiation. For example, riboflavin may be suitable as a photosensitizer. The content of riboflavin may be in the range of 0.0008w / v% to 0.008w / v%. Beyond this range, a gel with appropriate viscosity may not be formed. Preferably, the content of riboflavin may be in the range of 0.0008w / v% to 0.004w / v%.

[0075] Therefore, the weight ratio of collagen:riboflavin can be 1:0.00056 to 1:0.0533, within which the desired gel can be formed.

[0076] As the pH adjuster, NaOH or the like can be used. The content of the pH adjuster can be in the range of 26 mM to 30 mM. If it is outside this range, a gel having an appropriate viscosity may not be formed.

[0077] As isotonic agents, NaCl, KCl, a combination of Na2HPO4 and KH2PO4 can be used.

[0078] Next, light curing is performed ( S4 ).

[0079] like Figure 3 As shown, when irradiated with visible light, riboflavin as a photosensitizer is stimulated to undergo a chemical reaction, and the oxygen free radicals separated thereby form chemical bonding points on collagen, thereby solidifying the collagen.

[0080] LED light sources in the blue wavelength range are suitable as visible light sources. Although ultraviolet light can also achieve photocuring, it may cause damage to cells, so light sources in the blue wavelength range are suitable. As for the light source, a light source with a wavelength of 450nm can be irradiated with an output power and time sufficient to cure collagen. For example, the maximum output power can reach 2W / cm 2 The transplant site is irradiated for 20 to 60 seconds. The irradiation time will not make the patient feel hot, so that the photocurable composition is fully cured and will not flow, and can play a barrier function.

[0081] If necessary, the LED light irradiator is immersed (penetrated) into the in vivo absorbent photosensitive composition to more effectively transmit the light source so that the in vivo absorbent photosensitive composition is uniformly photocured as a whole. For example, in the case of treating periodontitis, the LED light irradiator can be immersed in the photocurable composition filled between the teeth and gums so that the light is evenly diffused into the photocurable composition to make photocuring easier.

[0082] The photocurable composition (e.g., collagen gel containing photosensitizer) is cross-linked by visible light, so that the collagen cross-linked by visible light fills the micro-voids of the transplant site and adheres to the transplant material, which can fix the transplant material. In addition, the collagen gel can also be combined with the natural collagen present in the transplant site. Therefore, regardless of the shape and size of the transplant site, the micro-voids of the transplant site are filled and combined with a strong adhesion force, so that the transplant material can be fixed. Therefore, the problems that arise when applying traditional barrier films can be solved, and the cumbersome process of suturing the barrier film is not required. When initially applied, the viscosity of the photocurable composition increases by about 1.5 times to 4.5 times from 25cP to 270cP to 110cP to 410cP through photocuring, thereby fitting with the transplant material at the bottom and preventing the transplant material from falling off.

[0083] In particular, when the transplant material is composed of a collagen block and a peptide having antibacterial or anti-inflammatory ability, the collagen block and the collagen sol are bonded, and not only the adhesion is enhanced, but also the effect of acting as a scaffold for the peptide having antibacterial or anti-inflammatory function to continue to act can be expected. For an ointment with minocycline as the main ingredient sold as a periodontitis treatment agent, since minocycline mainly exhibits only antibacterial effect, it is not sufficient to induce regeneration of the transplant site accompanied by inflammation, but when a peptide having antibacterial and anti-inflammatory ability is used, there is an advantage that the regeneration of the transplant site can be effectively induced.

[0084] In particular, in the case of periodontal disease, in addition to having antibacterial properties against periodontitis-causing bacteria, it can also reduce inflammation such as various peri-inflammations or periodontitis, thereby inducing an environment suitable for regeneration. In addition, collagen supports natural bone until it is fully regenerated, and decomposes due to absorption over time, thereby providing space for replacement by regenerated bone, thereby improving the efficiency of periodontal tissue regeneration.

[0085] Preferred experimental examples are given below to help understand the present invention, but the following experimental examples are only used to illustrate the present invention, and the scope of the present invention is not limited to the following experimental examples.

[0086] Peptide synthesis

[0087] For the peptide of sequence 1, the synthesis was performed from the C-terminus by F-moc solid phase chemical synthesis using a synthesis device. That is, Rink resin (0.075mmol / g, 100-200mesh, 1% DVB cross-linking) with Fmoc-(9-fluorenylmethoxycarbonyl) as a blocking group was used for synthesis. After adding 50mg of RinkAmide MBHA resin to the synthesizer, the resin was swollen with DMF, and then a 20% piperidine / DMF solution was used to remove the Fmoc-group. 5 equivalents, 10 equivalents, and 5 equivalents of 0.5M amino acid solution (solvent: DMF), 1.0M DIPEA (solvent: DMF&NMP), and 0.5M HBTU (solvent: DMF) were added from the C-terminus in sequence and reacted for 1-2 hours under a nitrogen flow. At the end of each deprotection and coupling step, the reaction mixture was washed twice with DMF and methanol. After the last amino acid was coupled, deprotection was performed to remove the Fmoc-group.

[0088] The synthesis was confirmed by the ninhydrin test. After the resin that had been synthesized was dried, 20 ml of Reagent K cleavage cocktail was added per gram of resin and shaken for 3 hours. The cocktail containing the resin and peptide was then separated by filtration. For the solution filtered by the filter, cold ether was added to crystallize the peptide into a solid phase, which was then centrifuged. At this time, the Reagent K cleavage cocktail was completely removed by washing with ether several times and centrifuging. The crude product thus obtained was dissolved in distilled water and separated and purified by liquid chromatography. The purified peptide was freeze-dried. The purity was analyzed by liquid chromatography, and the results of mass spectrometry are shown in FIG. Figure 4 and Figure 5 middle.

[0089] Reference Figure 4 and Figure 5 It was confirmed that the synthesized peptide had a purity of 98.2%, a molecular weight of 1733.99, and consisted of a 15-mer amino acid sequence.

[0090] Evaluation of anti-inflammatory ability

[0091] 1) Determination of the production of pro-inflammatory cytokines (IL-6 and TNF-α)

[0092] The anti-inflammatory ability was verified using human monocytic cell lines (THP-1, ATCC, TIB-202). For monocytic cell lines, PMA (phorbol 12-myristate-13-ethyl ester, Merck, P1585) was inoculated to differentiate from monocytes into macrophages, and then treated with 1μg / ml LPS (lipopolysaccharide, Merck, L3024) as an inflammatory mediator. After 16 hours, 200μM of a peptide with amino acids of sequence 1 and 20ng / ml of IL-4 (R&D system, 204-IL-010 / CF) were inoculated as a positive control group, and the culture fluid of the cells was obtained after 24 hours. The amount of proinflammatory cytokines IL-6 (R&D system, D6050) and TNF-α (R&D system, DTA00D) secreted by cells in the culture medium was confirmed by ELISA (enzyme-linked immunosorbent assay).

[0093] The results, such as Figure 6 As shown, it was confirmed that when treated with a peptide having the amino acid sequence of sequence 1 (LPS+S3), IL-6 and TNF-α values ​​were reduced to a level similar to that when treated with IL-4. When treated with LPS alone, IL-6 and TNF-α values ​​increased. This shows that the peptide having the amino acid sequence of sequence 1 has an anti-inflammatory effect.

[0094] 2) Western blotting of pNFkB and plkBa

[0095] Raw264.7 cells were purchased from ATCC (American Type Culture Collection) and used in the experiment. For Raw264.7 cells, DMEM (Dulbecco's Modified Eagle's) medium supplemented with 10% FBS and 100 unit / ml antibiotics (penicillin-streptomycin) was used and cultured in a CO2 incubator at 37°C supplied with 5% CO2 and 95% air.

[0096] Raw264.7 cells were treated with 200 μM of a peptide having the amino acid sequence of sequence 1 for 30 minutes, and then treated with 1 μg / ml LPS (lipopolysaccharide, Merck, L3024). After 8 hours, the treated cells were collected, and then a protease inhibitor cocktail and a phosphatase inhibitor cocktail were added to a radioimmunoprecipitation buffer (RIPA buffer solution, Thermo Fisher, 89900), and the cells were treated to lyse the cells. The cell lysate was centrifuged and the supernatant was recovered. The concentration of the cell lysate was then determined by the bicinchoninic acid method (BCA assay, Thermo Fisher, 23227). The cell lysate was finally made into 5 mg / ml by adding RIPA buffer solution. Then, it was mixed with a buffer solution composed of 1M Tris-HCl (pH 6.8), 50% glycerol, and 10% SDS in a ratio of 4:1, and then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Then, the polyacrylamide gel was transferred to a nitrocellulose membrane and blocked with a blocking solution (5% skim milk in Tris-buffered saline with 0.1% 20) After the membrane was blocked, the primary antibodies (phosphorylated NF-κB (Signaling Technology, 3033), NF-κB (Cell Signaling Technology, 8242), phosphorylated IκBα (Cell Signaling Technology, 9246), IκBα (Cell Signaling Technology, 4812), β-actin (Santa Cruz Biotechnology, sc-47778)) were reacted with the blocking solution at a ratio of 1:1000 under refrigeration overnight. Then, the secondary antibody corresponding to each primary antibody was reacted with the blocking solution at a ratio of 1:2000 at room temperature for 1 hour, and then reacted with ECL (enhanced chemiluminescence, Thermo Fisher, 34094) solution, and the membrane was developed using the ChemiDoc imaging system (Bio-Rad). Phosphorylated NF-κB and phosphorylated plkBa are indicators that can confirm the degree of inflammatory response at the cellular level. The higher the degree of inflammatory response, the more phosphorylated NF-κB and phosphorylated plkBa are expressed.

[0097] The results, such as Figure 7 As shown, when treated with LPS alone, the expression of pNFκB and plkBa increased, but when treated with a peptide having the amino acid sequence of sequence 1 and then treated with LPS, the expression of pNFκB and plkBa was inhibited. This shows that the peptide having the amino acid sequence of sequence 1 has an anti-inflammatory effect.

[0098] However, when treated only with a peptide having the amino acid sequence of sequence 1, the expression of pNFκB and plkBa of cells was not affected, which indirectly proved that the peptide was safe.

[0099] Evaluation of antimicrobial ability

[0100] 1) Inhibit the growth of periodontitis pathogens

[0101] In order to evaluate the antibacterial ability, representative periodontitis pathogens such as Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis were used. Each bacterium was inoculated into BHI (brain heart infusion) liquid culture medium and then cultured in an anaerobic incubator at 37°C and 120rpm for 48 hours. After cultivation, it was treated with a peptide having the amino acid sequence of sequence 1 to 100μM, 250μM, and 500μM. Minocycline (Merck, M9511) 500ng / ml was inoculated as a positive control group, and the absorbance was measured at a wavelength of 600nm using a spectrophotometer after 24 hours to confirm the growth degree of the bacteria.

[0102] The results, such as Figure 8 As shown, when treated with a peptide having the amino acid sequence of sequence 1, for Aa (Aggregatibacter actinomycetemcomitans), the bacterial survival rate was less than 50% when the concentration was above 250 μM, and for Pg (Porphyromonas gingivalis), the bacterial survival rate was less than 50% when the concentration was above 100 μM.

[0103] On the other hand, compared with the effect of minocycline, when Aa was treated at a concentration of 500 μM, the survival rate was higher than that when treated with minocycline 500 ng / ml, but similar effects were shown. In the case of minocycline, only antibacterial ability was present, while in the case of the peptide having the amino acid sequence of sequence 1, both antibacterial ability and anti-inflammatory ability were present, so even if there was a slight difference in antibacterial ability, that part could be compensated. For Pg, an effect superior to minocycline was shown in all concentration ranges.

[0104] 2) Evaluation of antibacterial ability in biofilm

[0105] Periodontitis-causing bacteria in the oral cavity exist in the form of biofilm. In order to simulate this situation, artificial biofilms were made on the surface of titanium disks using Aa (Aggregatibacter actinomycetemcomitans) and Pg (Porphyromonas gingivalis). Saliva and bacteria were mixed on the titanium disk and placed in BHI liquid culture medium, which was then cultured in an anaerobic incubator at 37°C. After 72 hours, 50μg / ml (=29μM), 100μg / ml (=58μM), 250μg / ml (=144μM), 500μg / ml (=288μM) of peptides were inoculated, and 1μg / ml of minocycline was inoculated as a positive control group. 24 hours after inoculation, a titanium disk with a biofilm formed on the surface was obtained, and Filmtracer was used to analyze the biofilm. TM LIVE / DEAD TM Biofilm viability kit (Thermo Fisher, L10316) was used to stain the biofilm. Live bacteria were stained green and dead bacteria were stained red. The titanium disk was observed using a confocal scanning fluorescence microscope.

[0106] The results, such as Fig. 9As shown, in the case of minocycline used as a positive control group, almost no bacteria (red) were observed to be killed, because it was not possible to penetrate the biofilm to kill bacteria. On the other hand, when the peptide having the amino acid sequence of sequence 1 was treated, bacteria (red) were observed to be killed starting from a concentration of 50 μg / ml (= 29 μM). Therefore, although the existing antibiotics cannot kill bacteria existing in the form of biofilms, in the case of the peptide having the amino acid sequence of sequence 1, it can be confirmed that it penetrates into the biofilm and has antibacterial ability.

[0107] Evaluation of cell / tissue penetration

[0108] 1) Evaluate cell permeability at the cellular level

[0109] The N-terminus of the peptide with amino acids of sequence 1 prepared in Example 1 was fluorescently labeled with rhodamine B (Tokyo Chemical Industry Co., Ltd., A5102). Raw264.7 cells were distributed to a 4-well chamber, 3X104 cells were distributed to each well, and cultured in DMEM medium for 24 hours to stabilize the cells. After 24 hours, the fluorescently labeled peptide was added to the culture medium at a concentration of 50, 100, and 200 μM. After 1 hour of peptide treatment, the degree of intracellular peptide penetration was observed using a confocal scanning fluorescence microscope. For the nucleus of the cell, 4', 6-diamidino-2-phenylindole (DAPI, Thermo Fisher, D1306) was used for staining. DIC represents the situation observed with an ordinary microscope, Nuceli represents the nucleus of the cell, Peptide represents the degree of penetration of the peptide bound to rhodamine B, and MERGE represents an image in which the images of DIC, Nuclei, and the infiltrated peptide are overlapped.

[0110] The results, such as Fig.10 As shown, the fluorescence of rhodamine B (red) was observed in cells treated with the peptide having the amino acid sequence 1, but no red color was observed in the untreated experimental group. In addition, it can be seen that the fluorescence intensity increases with the increase in peptide concentration.

[0111] 2) Evaluate tissue penetration in animal tissues

[0112] Using Alexa Fluor TM The amine groups of the peptides with the amino acids of sequence 1 were fluorescently labeled with 680 NHS ester (Thermo Fisher Scientific, A20008). The fluorescent labeling method followed the method provided by the manufacturer. The fluorescently labeled peptide was dissolved in water for injection at a concentration of 250 mg / ml, and 10 μL was injected into the gingival sulcus of the premolars of adult dogs (beagledog) and the gingival sulcus of the anterior teeth of rabbits (rabbit). After 2 hours, in order to confirm the penetration rate of the peptide in the tissue, the animals were sacrificed, the gingival tissue was collected and the gingival tissue was used for 30 min. The tissue was embedded in OCT Compound (Sakura Finetek, 4583). The embedded tissue was sliced ​​into 10 μm thick sections, and the fluorescently labeled peptide was confirmed using a confocal scanning fluorescence microscope. The nuclei of the tissue cells were stained with DAPI.

[0113] As a result, Fig.11 The gingival tissue of rabbits and Fig.12 The results of adult dog gingival tissue confirmed that the fluorescently labeled peptide penetrated the gingival tissue cells and reached a diameter of about 500 (440-459) μm.

[0114] Therefore, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 penetrates not only at the cellular level but also penetrates into tissues.

[0115] Evaluation of the antimicrobial capacity of transplant materials

[0116] A collagen sponge block of 6X5X7mm in size was impregnated with 500μg / 0.5ml of a peptide having amino acids of sequence 1, placed at 4°C for 8 hours, and then freeze-dried. As a positive control group, minocycline (Merck, M9511) 250ng / 0.5ml was impregnated with a collagen sponge block of 6X5X7mm in size, placed at 4°C for 8 hours, and then freeze-dried.

[0117] In order to evaluate the antibacterial ability of the transplant material containing the peptide with the amino acid sequence 1, representative periodontitis pathogens such as Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis were used. Each bacterium was inoculated into BHI (brain heart infusion) liquid culture medium and cultured in an anaerobic incubator at 37°C and 120rpm for 48 hours. After culture, the collagen sponge block containing the peptide with the amino acid sequence of sequence 1 of Example 2 was added to the culture medium. After 24 hours, the absorbance was measured at a wavelength of 600nm to confirm the growth degree of the bacteria.

[0118] The results, such as Fig.13 As shown, when the collagen sponge block containing the peptide having the amino acid sequence of sequence 1 was treated, the survival rate of bacteria for Aa (Aggregatibacter actinomycetemcomitans) and Pg (Porphyromonas gingivalis) was less than 40%. Therefore, it was proved that the peptide having the amino acid sequence of sequence 1 also had an antibacterial effect when applied to the collagen sponge block.

[0119] Evaluation of periodontal tissue regeneration ability of transplant materials

[0120] Collagen gel was dissolved in 0.1 M PBS at a concentration of 4%. 125 mg of the peptide having the amino acid sequence 1 was dissolved in 1 g of collagen gel. As a positive control group, 20 mg of minocycline was dissolved in the same 1 g of collagen gel.

[0121] In order to evaluate the periodontal tissue regeneration ability of transplant materials containing peptides with amino acids of sequence 1, collagen sponges containing peptides were implanted after periodontitis was induced in beagle dogs. To induce periodontitis, dental wire was used to wrap several layers around the necks of the 2nd, 3rd, and 4th teeth of the mandibular premolars to induce periodontitis. After wrapping the wire for three months, the wire was removed for scaling and root planning. 15μl of collagen gel containing peptides with amino acids of sequence 1 and collagen gel containing minocycline were applied to the gingival sulcus twice a week for 5 weeks. The periodontal status was observed for 12 weeks, and alveolar bone regeneration was observed by X-ray photography.

[0122] The results, such as Fig.14 and Fig.15 As shown, the group (NT) to which no substance was applied did not generate alveolar bone after 12 weeks. The group implanted with collagen gel containing minocycline showed a similar degree of alveolar bone regeneration as the NT group. However, when collagen gel using peptides with amino acids of sequence 1 was implanted, the regeneration of alveolar bone (white part in the box) increased by more than 10 times compared to the group implanted with collagen gel containing minocycline. Therefore, it was proved that collagen gel using peptides with amino acids of sequence 1 has an excellent effect on periodontal tissue regeneration.

[0123] Determination of gel formation according to the collagen content in the photocurable composition

[0124] Collagen gel containing riboflavin (riboflavin sodium phosphate, Sigma, 77623-50G-F) was prepared using porcine type 1 collagen. As shown in Table 1, gel was prepared by changing the concentration of collagen to 0.375w / v%, 0.75w / v%, 1.125w / v%, 1.5w / v%, and 3w / v%, and riboflavin and NaCl, KCl, Na2HPO4, KH2PO4, and NaOH were fixed to prepare collagen gel. Purified water was used as the solvent.

[0125]

Table 1

[0126] Components that vary the concentration of collagen solution

[0127]

[0128] The results, such as Fig.16 As shown, it was confirmed that gel formation began at 0.75% collagen, and the hardest gel was formed at 3%.

[0129] Determination of gel formation according to the riboflavin content in the photocurable composition

[0130] As shown in Table 2, gel was prepared by changing the concentration of riboflavin to 0.0008 w / v%, 0.0016 w / v%, 0.004 w / v%, and 0.008 w / v%, and collagen and NaCl, KCl, Na2HPO4, KH2PO4, and NaOH were fixed to prepare collagen gel. Purified water was used as the solvent.

[0131]

Table 2

[0132] Components that change the concentration of riboflavin solution

[0133]

[0134] The results, such as Fig.17 A gel having an appropriate viscosity is formed in the range of 0.0008 w / v% to 0.008 w / v%, and a gel having a more preferred viscosity is formed in the range of 0.0008 w / v% to 0.004 w / v%.

[0135] Determination of gel formation according to the NaOH content in the photocurable composition

[0136] As shown in Table 3, gel was prepared by changing the concentration of NaOH to 20 mM, 26 mM, and 30 mM, and collagen, riboflavin, NaCl, KCl, Na2HPO4, and KH2PO4 were fixed to prepare collagen gel. Purified water was used as the solvent.

[0137]

Table 3

[0138] Components that change the pH adjuster concentration

[0139]

[0140] The results, such as Fig.18 As shown, no gel was formed at 20 mM NaOH, but gel was formed at 26 mM and 30 mM NaOH.

[0141] Changes in properties of a photocurable composition (collagen gel containing riboflavin) upon light irradiation

[0142] 300 μl of the collagen gel of component number 4 in Table 1 was irradiated with light having a wavelength of 450 nm and a power of 2 W / cm 2The intensity of irradiation was set at 10 s, 20 s, 30 s, 50 s, and 60 s, and the shape of the collagen gel was observed.

[0143] The results are as follows Fig.19 See Fig.19 , when irradiated with light for 10 seconds, no phase change occurred. When irradiated with light for 20 seconds, it began to solidify and transform into a solid state, and became a solid state after 30 seconds.

[0144] Determination of viscosity of photocurable composition

[0145] The gels of component numbers 2 to 5 shown in Table 1 were measured using a viscometer (DV-II Pro Viscometer, Brookfield). A No. 42 spindle was used for the measurement, and the viscosity before and after curing was measured at 90 rpm.

[0146] The results are as follows Fig. 20 See Fig. 20 , it was determined that the viscosity of the gel of components 2 to 5 before curing was between 25 and 270 cP, and the viscosity after curing increased to 110 to 410 cP. That is, although there are differences depending on the components, the viscosity after curing can be increased by about 1.5 to 4 times compared to before curing.

[0147] Stability of collagen gel containing riboflavin

[0148] In order to confirm the stability of the collagen gel containing riboflavin, the collagen gel of component number 4 in Table 1 was irradiated with light for 30 seconds, placed in 500 μl of pure water, and stored at 37°C for 7 days, 14 days, and 30 days. The collagen gel of component number 4 was not irradiated with light as a control group, and was placed in 500 μl of pure water and stored at 37°C for 7 days, 14 days, and 30 days.

[0149] The results are as follows Fig.21 See Fig.21 , the gel placed in pure water after irradiation with light for 30 seconds maintained its shape, while the gel not irradiated with light did not maintain its shape when mixed with pure water. Therefore, it was confirmed that the collagen gel containing riboflavin of component number 4 irradiated with light for 30 seconds could stably form a solid gel for up to 30 days.

[0150] Adaptation of collagen gel containing riboflavin as transplant material

[0151] The collagen gel containing riboflavin can be used locally in the body, such as when a collagen block needs to be fixed. The collagen gel of component number 4 in Table 1 was applied to artificially induced peri-implantitis in adult dogs. Fig. 22As shown in the figure, the gums at the site of peri-implantitis were cut open and the area around the implant was cleaned with saline as much as possible. After cleaning, the collagen block containing peptides was implanted into the site of peri-implantitis ( Fig. 22 a). After transplantation, 0.5 ml of collagen gel containing riboflavin was applied to fix the collagen block. Fig. 22 b) Then use light with a wavelength of 450nm at 2W / cm 2 Irradiate for 30 seconds at an intensity of Fig. 22 c). After confirming that the collagen gel containing riboflavin has gelled, suture the cut gums ( Fig. 22 d) It was confirmed that the transplanted site remained in good condition 4 weeks after the transplantation without any side effects.

[0152] Although the experimental examples are described above, the scope of the rights is not limited thereto. Within the scope of the specification and the drawings, the implementation method can be modified into various methods, which of course also fall within the scope of the rights.

[0153] Industrial Applicability

[0154] It can be used as a transplant material for treating various bone loss or defects caused by inflammation, tumors, trauma, bone diseases, etc.

[0155] Sequence Listing Free Text

[0156] Sequence Listing No. 1: GKCSTRGRKS SRRKK

[0157] Sequence Listing No. 2: CPRRYKQIGT CGLPGTKCCK KP

[0158] Sequence Listing No.3: GKCSTRGRKC CRRKK

[0159] Sequence Listing No. 4: RKIEIVRKKP IFKKATVT

[0160] Sequence Listing No. 5: CKRKKKGKGL GKKRDPCLRK YK

Claims

1. A photocurable composition for in vivo absorption, wherein: The in vivo absorbable photocurable composition comprises a photosensitizer and collagen, Applying the coating to the top of the implantation site in the body filled with the implantation material to fill the gap in the implantation site and cover the implantation material, The photosensitizer is activated by irradiation with visible light, and the collagen is cross-linked. The collagen cross-linked by the visible light fills the fine gaps in the transplantation site and adheres to the transplantation material to fix the transplantation material.

2. The in vivo absorbable photocurable composition according to claim 1, wherein The viscosity of the photocurable composition after the visible light irradiation increases by 1.5 to 4.5 times compared to that before the visible light irradiation.

3. The in vivo absorbable photocurable composition according to claim 1, wherein The photosensitizer is riboflavin.

4. The in vivo absorbable photocurable composition according to claim 3, wherein The weight ratio of riboflavin to collagen is 1:0.00056 to 1:0533.

5. The in vivo absorbable photocurable composition according to claim 3, wherein The visible light is a light source in the blue wavelength range, with a maximum output power of 2W / cm 2 .

6. An in vivo absorbable tissue regeneration inducing material, wherein: The in vivo absorbable tissue regeneration inducing material comprises a transplant material and an in vivo absorbable photocurable composition, wherein the transplant material comprises a first agent and a second agent, wherein the first agent comprises collagen as a main component, and the second agent comprises a peptide formulated to be able to impregnate the first agent, and the in vivo absorbable photocurable composition comprises a photosensitizer and collagen, which is applied to a transplant site filled with the transplant material to fill the gaps in the transplant site and cover the transplant material, wherein the photosensitizer is activated by irradiation with visible light, and the collagen is cross-linked, and the collagen cross-linked by the visible light fills the fine gaps in the transplant site and adheres to the transplant material to fix the transplant material.

7. The in vivo absorbable tissue regeneration inducing material according to claim 6, wherein: The peptide is a peptide with antibacterial ability, anti-inflammatory ability, antibacterial ability and anti-inflammatory ability, antibacterial ability, anti-inflammatory ability and cell penetration ability.

8. The in vivo absorbable tissue regeneration inducing material according to claim 7, wherein: The peptide is a peptide represented by any one of the amino acid sequences in Sequences 1 to 5.

9. The in vivo absorbable tissue regeneration inducing material according to claim 7, wherein: The transplant material comprises 10 -4 ~0.5 parts by weight of the peptide.

10. The in vivo absorbable tissue regeneration inducing material according to claim 6, wherein The viscosity of the photocurable composition after the visible light irradiation increases by 1.5 to 4.5 times compared to that before the visible light irradiation.

11. The in vivo absorbable tissue regeneration inducing material according to claim 6, wherein: The photosensitizer is riboflavin.

12. The in vivo absorbable photocurable composition according to claim 11, wherein The weight ratio of riboflavin to collagen is 1:0.00056 to 1:0.0533.

13. The in vivo absorbable tissue regeneration inducing material according to claim 6, wherein: The visible light is a light source in the blue wavelength range, with a maximum output power of 2W / cm 2 .

14. A transplantation method, comprising: The step of filling the transplant material into the transplant site in the body; The step of coating a photocurable composition in vivo absorbable containing a photosensitizer and collagen on the top of the transplant site filled with the transplant material to fill the gap in the transplant site and cover the transplant material; and The process comprises: irradiating the body-absorbable photocurable composition with visible light, activating the photosensitizer, causing the collagen to cross-link, filling the fine gaps in the transplantation site with the collagen cross-linked by the visible light, and adhering to the transplantation material to fix the transplantation material.

15. The transplantation method according to claim 14, wherein: Before the step of filling the graft material, The method also comprises the step of pretreating the in vivo transplantation site.

16. The transplantation method according to claim 15, wherein: The transplant site is a periodontal disease site, The pretreatment steps include scaling or scaling and root planing.

17. The transplantation method according to claim 14, wherein: The viscosity of the photocurable composition after the visible light irradiation increases by 1.5 to 4.5 times compared to that before the visible light irradiation.

18. The transplantation method according to claim 14, wherein: The photosensitizer is riboflavin.

19. The transplantation method according to claim 18, wherein: The weight ratio of riboflavin to collagen is 1:0.00056 to 1:0.0533.

20. The transplantation method according to claim 14, wherein: The visible light is a light source in the blue wavelength range, with a maximum output power of 2W / cm 2 .

21. The transplantation method according to claim 14, wherein: The light irradiator for irradiating the visible light is immersed in the in vivo absorptive photosensitive composition to transmit the light source.

22. The transplantation method according to claim 14, wherein: The transplant material comprises a first agent and a second agent, wherein the first agent has collagen as a main component, and the second agent comprises a peptide formulated to be able to impregnate the first agent.

23. The transplantation method according to claim 22, wherein: The peptide is a peptide with antibacterial ability, anti-inflammatory ability, antibacterial ability and anti-inflammatory ability, antibacterial ability, anti-inflammatory ability and cell penetration ability.

24. The transplantation method according to claim 23, wherein: The peptide is a peptide represented by any one of the amino acid sequences in Sequences 1 to 5.

25. The transplantation method according to claim 23, wherein: The transplant material comprises 10 -4 ~0.5 parts by weight of the peptide.

Citation Information

Patent Citations

  • Antibacterial or Anti-inflammatory Peptides and Pharmaceutical Composition Containing Thereof

    KR101249702B1

  • Antibacterial or Anti-inflammatory Peptides and Pharmaceutical Composition Containing Thereof

    KR101257228B1

  • Antibacterial or Anti-inflammatory Peptides and Pharmaceutical Composition Containing Thereof

    KR101320472B1

  • Antibacterial or Anti-inflammatory Peptides and Pharmaceutical Composition Containing Thereof

    KR101329774B1